Final Assessment: Myelodysplastic Syndrome (MDS)

Primary Audience:

Hematologist-Oncologists, Oncologists

Relevant Terms:

Myelodysplastic Syndrome

In this last activity, you will evaluate several case-based scenarios now that you have completed the educational modules.
Incorporate the evidence-based data and expert recommendations regarding the initiation of treatments for anemia due to MDS.
Employ expert guidance in the management of adverse events related to luspatercept in patients with low-risk MDS.
Optimally titrate luspatercept to help ensure treatment success.
Apply knowledge of emerging treatments to management decisions in patients with MDS.